<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>115(7)</volume><submitter>Hyde RK</submitter><funding>Intramural NIH HHS</funding><pubmed_abstract>It is known that CBFB-MYH11, the fusion gene generated by inversion of chromosome 16 in human acute myeloid leukemia, is causative for oncogenic transformation. However, the mechanism by which CBFB-MYH11 initiates leukemogenesis is not clear. Previously published reports showed that CBFB-MYH11 dominantly inhibits RUNX1 and CBFB, and such inhibition has been suggested as the mechanism for leukemogenesis. Here we show that Cbfb-MYH11 caused Cbfb/Runx1 repression-independent defects in both primitive and definitive hematopoiesis. During primitive hematopoiesis, Cbfb-MYH11 delayed differentiation characterized by sustained expression of Gata2, Il1rl1, and Csf2rb, a phenotype not found in Cbfb and Runx1 knockout mice. Expression of Cbfb-MYH11 in the bone marrow induced the accumulation of abnormal progenitor-like cells expressing Csf2rb in preleukemic mice. The expression of all 3 genes was detected in most human and murine CBFB-MYH11(+) leukemia samples. Interestingly, Cbfb-MYH11(+) preleukemic progenitors and leukemia-initiating cells did not express Csf2rb, although the majority of leukemia cells in our Cbfb-MYH11 knockin mice were Csf2rb(+). Therefore Csf2rb can be used as a negative selection marker to enrich preleukemic progenitor cells and leukemia-initiating cells from Cbfb-MYH11 mice. These results suggest that Cbfb/Runx1 repression-independent activities contribute to leukemogenesis by Cbfb-MYH11.</pubmed_abstract><journal>Blood</journal><pagination>1433-43</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC2826765</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Cbfb/Runx1 repression-independent blockage of differentiation and accumulation of Csf2rb-expressing cells by Cbfb-MYH11.</pubmed_title><pmcid>PMC2826765</pmcid><pubmed_authors>Zhao L</pubmed_authors><pubmed_authors>Kamikubo Y</pubmed_authors><pubmed_authors>Liu PP</pubmed_authors><pubmed_authors>Anderson S</pubmed_authors><pubmed_authors>Alemu L</pubmed_authors><pubmed_authors>Hyde RK</pubmed_authors><pubmed_authors>Kirby M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Cbfb/Runx1 repression-independent blockage of differentiation and accumulation of Csf2rb-expressing cells by Cbfb-MYH11.</name><description>It is known that CBFB-MYH11, the fusion gene generated by inversion of chromosome 16 in human acute myeloid leukemia, is causative for oncogenic transformation. However, the mechanism by which CBFB-MYH11 initiates leukemogenesis is not clear. Previously published reports showed that CBFB-MYH11 dominantly inhibits RUNX1 and CBFB, and such inhibition has been suggested as the mechanism for leukemogenesis. Here we show that Cbfb-MYH11 caused Cbfb/Runx1 repression-independent defects in both primitive and definitive hematopoiesis. During primitive hematopoiesis, Cbfb-MYH11 delayed differentiation characterized by sustained expression of Gata2, Il1rl1, and Csf2rb, a phenotype not found in Cbfb and Runx1 knockout mice. Expression of Cbfb-MYH11 in the bone marrow induced the accumulation of abnormal progenitor-like cells expressing Csf2rb in preleukemic mice. The expression of all 3 genes was detected in most human and murine CBFB-MYH11(+) leukemia samples. Interestingly, Cbfb-MYH11(+) preleukemic progenitors and leukemia-initiating cells did not express Csf2rb, although the majority of leukemia cells in our Cbfb-MYH11 knockin mice were Csf2rb(+). Therefore Csf2rb can be used as a negative selection marker to enrich preleukemic progenitor cells and leukemia-initiating cells from Cbfb-MYH11 mice. These results suggest that Cbfb/Runx1 repression-independent activities contribute to leukemogenesis by Cbfb-MYH11.</description><dates><release>2010-01-01T00:00:00Z</release><publication>2010 Feb</publication><modification>2024-02-16T08:19:17.077Z</modification><creation>2019-06-06T21:54:19Z</creation></dates><accession>S-EPMC2826765</accession><cross_references><pubmed>20007544</pubmed><doi>10.1182/blood-2009-06-227413</doi></cross_references></HashMap>